A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
Each subject will be given a single oral dose of rosuvastatin on Day 1 in Period 1. In Period
2, after a washout period of at least 5 days, each subject will receive oral doses of
tafamidis twice daily (BID) on days 1 and 2, followed by tafamidis once daily (QD) on days 3
to 9 with an oral dose of rosuvastatin on Day 7. Rosuvastatin exposures will be compared
between Periods 1 and 2 to estimate the effect of tafamidis on rosuvastatin PK in healthy
subjects.